+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
ID05202314

Immunotherapy With Camrelizumab and Chemotherapy After Stent Placement Before Surgery for Left-Sided Obstructive Colorectal Cancer

Led by Beijing Chao Yang Hospital · Updated on 2023-02-21

20

Participants Needed

1

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Patients with obstruction in the left colon or upper rectum due to colorectal cancer often face worse outcomes compared to those without obstruction. Emergency surgery for malignant large bowel obstruction has high rates of complications and mortality, with many patients ending up with a permanent stoma. Self-expanding metallic stents SEMS have been used to relieve obstruction before elective surgery, showing better short-term outcomes. However, long-term results for SEMS are unclear and may involve risks such as tumor cell spread. Immunotherapy combined with chemotherapy after stenting is being studied to improve survival and surgical success rates regardless of tumor genetic status. In this study, after successful colonic stenting, patients receive two cycles of immunotherapy with Camrelizumab combined with either three cycles of mFOLFOX6 chemotherapy or two cycles of CapeOx chemotherapy. Surgery is scheduled 2 to 3 weeks after the last chemotherapy cycle, with the type of surgery determined by the surgeon. This approach aims to allow more time for bowel decompression, increase the rate of successful bowel reconnection primary anastomosis, reduce the need for stoma formation, and potentially improve overall and progression-free survival. Participants will be closely monitored with pathological examinations two weeks after surgery to assess complete remission. Researchers will also follow participants for up to three years after surgery to evaluate disease-free survival and overall survival. Throughout the study, patients undergo routine assessments of blood counts, organ function, and physical condition to ensure safety and treatment effectiveness. The total duration of participation varies depending on treatment and follow-up timelines.

CONDITIONS

Brief Title

Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer

Research Team

J

Jia Gang Han, MD

Z

Zhi Wei Zhai, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here